Indications |
Oral Mild to moderate dementia Adult: 3-4.5 mg daily. May also be given via sublingual admin. |
Contraindications |
Hypersensitivity. |
Warnings / Precautions |
Pregnancy. Severe bradycardia. |
Adverse Reactions |
Abdominal cramps, nausea, vomiting, headache, blurred vision, skin rashes, nasal congestion, flushing of the skin, dizziness, orthostatic hypotension, bradycardia. |
Mechanism of Actions |
Co-dergocrine mesylate is a complex of 4 hydrogenated ergot alkaloids.It acts at the central synapsi causing dopaminergic and serotonergic actions while reducing noradrenergic activity in the limbic and other areas. Age-related symptoms and signs such as loss of recent memory, confusion, poor concentration, disorientation, apathy, depression, difficulty in self-care and unsociability are improved. Absorption: Oral: Rapidly absorbed from the GI tract; plasma levels peak about 1-2 hr after a dose. Distribution: 81% bound to plasma proteins. Metabolism: Extensive first-pass effect. Excretion: Mainly in bile via the faeces, via urine (small amounts); elimination T1/2 (biphasic): 1.5-2.5 hr (α-phase), 13-15 hr (β-phase). |
Storage Conditions |
Oral: Store below 25°C. |
ATC Classification |
C04AE04 - dihydroergocristine ; Belongs to the class of ergot alkaloids. Used as peripheral vasodilators. |
Storage |
Oral: Store below 25°C. |
Available As |
|
Codergocrine Mesylate
Post Review about Codergocrine Mesylate Click here to cancel reply.
Codergocrine Mesylate Containing Brands
Codergocrine Mesylate is used in following diseases
Drug - Drug Interactions of Codergocrine Mesylate
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.